نتایج جستجو برای: vhl

تعداد نتایج: 1947  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2004
William G Kaelin

The von Hippel-Lindau tumor suppressor gene (VHL), which resides on chromosome 3p25, is mutated or silenced in >50% of sporadic clear cell renal cell carcinomas. Germ-line VHL mutations give rise to VHL disease, which is characterized by an increased risk of blood vessel tumors (hemangioblastomas) and renal cell carcinomas. In this setting, VHL inactivation gives rise to premalignant renal cyst...

Journal: :Science 1999
C E Stebbins W G Kaelin N P Pavletich

Mutation of the VHL tumor suppressor is associated with the inherited von Hippel-Lindau (VHL) cancer syndrome and the majority of kidney cancers. VHL binds the ElonginC-ElonginB complex and regulates levels of hypoxia-inducible proteins. The structure of the ternary complex at 2.7 angstrom resolution shows two interfaces, one between VHL and ElonginC and another between ElonginC and ElonginB. T...

Journal: :Carcinogenesis 2011
Lokesh Dalasanur Nagaprashantha Rit Vatsyayan Jyotsana Singhal Poorna Lelsani Laszlo Prokai Sanjay Awasthi Sharad S Singhal

Renal cell carcinoma (RCC) is one of the top ten cancers prevalent in USA. Loss-of-function mutations in the von Hippel-Lindau (VHL) gene constitute an established risk factor contributing to 75% of total reported cases of RCC. Loss-of-VHL leads to a highly vascularized phenotype of renal tumors. Intake of citrus fruits has been proven to reduce the risk of RCC in multicenter international stud...

2011
Lee E. Moore Michael L. Nickerson Paul Brennan Jorge R. Toro Erich Jaeger Jessica Rinsky Summer S. Han David Zaridze Vsevolod Matveev Vladimir Janout Hellena Kollarova Vladimir Bencko Marie Navratilova Neonilia Szeszenia-Dabrowska Dana Mates Laura S. Schmidt Petra Lenz Sara Karami W. Marston Linehan Maria Merino Stephen Chanock Paolo Boffetta Wong-Ho Chow Frederic M. Waldman Nathaniel Rothman

Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal canc...

2013
Yun Hyi Ku Chang Ho Ahn Chan-Hyeon Jung Jie Eun Lee Lee-Kyung Kim Soo Heon Kwak Hye Seung Jung Kyong Soo Park Young Min Cho

BACKGROUND Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited, multisystemic tumor syndrome caused by mutations in the VHL gene. To date, more than 1,000 germline and somatic mutations of the VHL gene have been reported. We present a novel mutation in the VHL tumor suppressor gene that presented with gestational diabetes mellitus. METHODS A 30-year-old woman presented with g...

Journal: :Onkologie 2005
Markus Joerger Dieter Koeberle Hartmut P H Neumann Silke Gillessen

INTRODUCTION Von Hippel-Lindau disease (VHL) is an autosomal dominant multisystemic cancer syndrome due to a mutation of the VHL tumor suppressor gene on chromosome 3, region p25-26, with an incidence of 1/36,000 in newborns. Patients are at risk of developing cerebellar, spinal and retinal hemangioblastoma, renal cell carcinoma, pheochromocytoma, pancreatic neuroendocrine tumors, pancreatic an...

2014
David A. Rowbotham Katey S. S. Enfield Victor D. Martinez Kelsie L. Thu Emily A. Vucic Greg L. Stewart Kevin L. Bennewith Wan L. Lam

Pheochromocytomas (PCC) are rare tumors that arise in chromaffin tissue of the adrenal gland. PCC are frequently inherited through predisposing mutations in genes such as the von Hippel-Lindau (VHL) tumor suppressor. VHL is part of the VHL elongin BC protein complex that also includes CUL2/5, TCEB1, TCEB2, and RBX1; in normoxic conditions this complex targets hypoxia-inducible factor 1 alpha (H...

Journal: :The Journal of clinical investigation 2015
Ana Martins Metelo Haley R Noonan Xiang Li Youngnam Jin Rania Baker Lee Kamentsky Yiyun Zhang Ellen van Rooijen Jordan Shin Anne E Carpenter Jing-Ruey Yeh Randall T Peterson Othon Iliopoulos

Patients with a germline mutation in von Hippel-Lindau (VHL) develop renal cell cancers and hypervascular tumors of the brain, adrenal glands, and pancreas as well as erythrocytosis. These phenotypes are driven by aberrant expression of HIF2α, which induces expression of genes involved in cell proliferation, angiogenesis, and red blood cell production. Currently, there are no effective treatmen...

Journal: :Oncology letters 2015
Lei Zhang Bin Xu Yiduo Wang Chunhui Liu Kai Lu Yeqing Huang Ning Liu Xiaowen Zhang Shuqiu Chen Ming Chen

The autosomal dominant hereditary disorder von Hippel-Lindau (VHL) disease is caused by a germline mutation in the VHL gene. The symptoms of VHL include hemangioblastoma of the central nervous system, retinal angiomas, visceral tumors and multiple visceral cysts. However, advanced renal cell carcinoma (RCC) occurs in few VHL patients at initial diagnosis; in addition, sporadic VHL disease with ...

Journal: :PLoS Biology 2004
Tammie Bishop Kah Weng Lau Andrew C. R Epstein Stuart K Kim Min Jiang Delia O'Rourke Christopher W Pugh Jonathan M Gleadle Martin S Taylor Jonathan Hodgkin Peter J Ratcliffe

The von Hippel-Lindau (VHL) tumor suppressor functions as a ubiquitin ligase that mediates proteolytic inactivation of hydroxylated alpha subunits of hypoxia-inducible factor (HIF). Although studies of VHL-defective renal carcinoma cells suggest the existence of other VHL tumor suppressor pathways, dysregulation of the HIF transcriptional cascade has extensive effects that make it difficult to ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید